Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome

Keslie S. Woods, Rosario Reyna, Ricardo Azziz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To determine whether the use of oral micronized progesterone (OMP) to induce withdrawal bleeding in women suspected of having polycystic ovary syndrome (PCOS) alters circulating androgen levels. Design: Prospective clinical trial. Setting: Academic medical center. Patient(s): Eight reproductive-aged women with PCOS. Intervention(s): Blood was sampled before (week 0) and weekly after (weeks 1 to 4) the administration of OMP (Prometrium, Solvay Pharmaceuticals, Marietta, GA), 100 mg in the morning and 200 mg before bedtime for 7 days. Main Outcome Measure(s): The levels of total testosterone (TT), free testosterone (FT), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), and androstenedione (A4) were determined in the blood samples. Result(s): In seven of the eight women studied, menstrual cycle intervals were >3 months, while one was eumenorrheic; six of the eight women had hirsutism (modified Ferriman-Gallwey score >7). Mean age was 28.9 ± 10.4 years and mean body mass index was 33.9 ± 4.7 kg/m2. The mean values of TT, FT, SHBG, DHEAS, A4, and 17-OHP did not change with OMP administration. However, a higher 17-OHP level was observable at the completion of OMP administration (week 2). Conclusion(s): We conclude that the administration of OMP (100 mg in the morning and 200 mg before bedtime for 7 days) to induce withdrawal bleeding in women with PCOS does not significantly alter circulating androgen or 17-OHP levels, and can be used to time blood sampling in these patients.

Original languageEnglish (US)
Pages (from-to)1125-1127
Number of pages3
JournalFertility and sterility
Volume77
Issue number6
DOIs
StatePublished - Jun 24 2002

Fingerprint

Polycystic Ovary Syndrome
Androgens
Progesterone
Testosterone
Sex Hormone-Binding Globulin
Dehydroepiandrosterone Sulfate
Oral Administration
Hemorrhage
Hirsutism
Androstenedione
Menstrual Cycle
Body Mass Index
Outcome Assessment (Health Care)
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Androgens
  • Blood sampling
  • Hyperandrogenism
  • Polycystic ovary syndrome
  • Progesterone

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome. / Woods, Keslie S.; Reyna, Rosario; Azziz, Ricardo.

In: Fertility and sterility, Vol. 77, No. 6, 24.06.2002, p. 1125-1127.

Research output: Contribution to journalArticle

Woods, Keslie S. ; Reyna, Rosario ; Azziz, Ricardo. / Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome. In: Fertility and sterility. 2002 ; Vol. 77, No. 6. pp. 1125-1127.
@article{c77fdb1f555e41b8a00779a119bf8643,
title = "Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome",
abstract = "Objective: To determine whether the use of oral micronized progesterone (OMP) to induce withdrawal bleeding in women suspected of having polycystic ovary syndrome (PCOS) alters circulating androgen levels. Design: Prospective clinical trial. Setting: Academic medical center. Patient(s): Eight reproductive-aged women with PCOS. Intervention(s): Blood was sampled before (week 0) and weekly after (weeks 1 to 4) the administration of OMP (Prometrium, Solvay Pharmaceuticals, Marietta, GA), 100 mg in the morning and 200 mg before bedtime for 7 days. Main Outcome Measure(s): The levels of total testosterone (TT), free testosterone (FT), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), and androstenedione (A4) were determined in the blood samples. Result(s): In seven of the eight women studied, menstrual cycle intervals were >3 months, while one was eumenorrheic; six of the eight women had hirsutism (modified Ferriman-Gallwey score >7). Mean age was 28.9 ± 10.4 years and mean body mass index was 33.9 ± 4.7 kg/m2. The mean values of TT, FT, SHBG, DHEAS, A4, and 17-OHP did not change with OMP administration. However, a higher 17-OHP level was observable at the completion of OMP administration (week 2). Conclusion(s): We conclude that the administration of OMP (100 mg in the morning and 200 mg before bedtime for 7 days) to induce withdrawal bleeding in women with PCOS does not significantly alter circulating androgen or 17-OHP levels, and can be used to time blood sampling in these patients.",
keywords = "Androgens, Blood sampling, Hyperandrogenism, Polycystic ovary syndrome, Progesterone",
author = "Woods, {Keslie S.} and Rosario Reyna and Ricardo Azziz",
year = "2002",
month = "6",
day = "24",
doi = "10.1016/S0015-0282(02)03119-9",
language = "English (US)",
volume = "77",
pages = "1125--1127",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome

AU - Woods, Keslie S.

AU - Reyna, Rosario

AU - Azziz, Ricardo

PY - 2002/6/24

Y1 - 2002/6/24

N2 - Objective: To determine whether the use of oral micronized progesterone (OMP) to induce withdrawal bleeding in women suspected of having polycystic ovary syndrome (PCOS) alters circulating androgen levels. Design: Prospective clinical trial. Setting: Academic medical center. Patient(s): Eight reproductive-aged women with PCOS. Intervention(s): Blood was sampled before (week 0) and weekly after (weeks 1 to 4) the administration of OMP (Prometrium, Solvay Pharmaceuticals, Marietta, GA), 100 mg in the morning and 200 mg before bedtime for 7 days. Main Outcome Measure(s): The levels of total testosterone (TT), free testosterone (FT), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), and androstenedione (A4) were determined in the blood samples. Result(s): In seven of the eight women studied, menstrual cycle intervals were >3 months, while one was eumenorrheic; six of the eight women had hirsutism (modified Ferriman-Gallwey score >7). Mean age was 28.9 ± 10.4 years and mean body mass index was 33.9 ± 4.7 kg/m2. The mean values of TT, FT, SHBG, DHEAS, A4, and 17-OHP did not change with OMP administration. However, a higher 17-OHP level was observable at the completion of OMP administration (week 2). Conclusion(s): We conclude that the administration of OMP (100 mg in the morning and 200 mg before bedtime for 7 days) to induce withdrawal bleeding in women with PCOS does not significantly alter circulating androgen or 17-OHP levels, and can be used to time blood sampling in these patients.

AB - Objective: To determine whether the use of oral micronized progesterone (OMP) to induce withdrawal bleeding in women suspected of having polycystic ovary syndrome (PCOS) alters circulating androgen levels. Design: Prospective clinical trial. Setting: Academic medical center. Patient(s): Eight reproductive-aged women with PCOS. Intervention(s): Blood was sampled before (week 0) and weekly after (weeks 1 to 4) the administration of OMP (Prometrium, Solvay Pharmaceuticals, Marietta, GA), 100 mg in the morning and 200 mg before bedtime for 7 days. Main Outcome Measure(s): The levels of total testosterone (TT), free testosterone (FT), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), and androstenedione (A4) were determined in the blood samples. Result(s): In seven of the eight women studied, menstrual cycle intervals were >3 months, while one was eumenorrheic; six of the eight women had hirsutism (modified Ferriman-Gallwey score >7). Mean age was 28.9 ± 10.4 years and mean body mass index was 33.9 ± 4.7 kg/m2. The mean values of TT, FT, SHBG, DHEAS, A4, and 17-OHP did not change with OMP administration. However, a higher 17-OHP level was observable at the completion of OMP administration (week 2). Conclusion(s): We conclude that the administration of OMP (100 mg in the morning and 200 mg before bedtime for 7 days) to induce withdrawal bleeding in women with PCOS does not significantly alter circulating androgen or 17-OHP levels, and can be used to time blood sampling in these patients.

KW - Androgens

KW - Blood sampling

KW - Hyperandrogenism

KW - Polycystic ovary syndrome

KW - Progesterone

UR - http://www.scopus.com/inward/record.url?scp=0036282584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036282584&partnerID=8YFLogxK

U2 - 10.1016/S0015-0282(02)03119-9

DO - 10.1016/S0015-0282(02)03119-9

M3 - Article

C2 - 12057716

AN - SCOPUS:0036282584

VL - 77

SP - 1125

EP - 1127

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -